Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin

NCT00082381 · Completed

Last updated 2026-05-28

This clinical trial is testing the medication AC2993 against insulin glargine in adults with type 2 diabetes who are already taking sulfonylurea and metformin.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 551 people

Who can join Ages 30–75 · all sexes

Timeline Started 2003-06 · est. completion 2008-07

Where 91 sites · Australia, Belgium, Brazil, Finland, Germany, Netherlands, Norway, Poland, Portugal, Puerto Rico, Spain, Sweden, United States

What this study is testing ClinicalTrials.gov NCT00082381 ↗

Description as written by the study sponsor.

This is a multicenter, comparator-controlled, open-label, randomized, two-arm, parallel trial to compare the effect of exenatide twice daily and insulin glargine on glycemic control, as measured by hemoglobin A1c (HbA1c).

Treatments tested

Exenatide (AC2993) also known as Byetta Drug

subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
Insulin glargine also known as Lantus Drug

subcutaneous injection, once daily; forced titration to target blood glucose level

Main thing measured	Change in Glycosylated Hemoglobin (HbA1c)
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00082381 ↗